Specific Uptake of the Auger Electron-emitting Thymidine Analogue 5-[123I/125I]Iodo-2′-deoxyuridine in Rat Brain Tumors: Diagnostic and Therapeutic Implications in Humans
Open/View files
Date
1990
Author(s)
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Kassis A. I., A. D. Van den Abbeele, P. Y. Wen, J. Baranowska-Kortylewicz, R. A. Aaronson, W. C. DeSisto, L. A. Lampson, P. M. Black, and S. J. Adelstein. 1990. Specific Uptake of the Auger Electron-emitting Thymidine Analogue 5-[123I/125I]Iodo-2′-deoxyuridine in Rat Brain Tumors: Diagnostic and Therapeutic Implications in Humans. Cancer Research 50, no. 16.
Abstract
Glial neoplasms of the human central nervous system are malignancies that have defied treatment. Part of the problem lies in the limitations of current diagnostic techniques which are unable to identify small collections of neoplastic glia within normal parenchyma and in the difficulty of sterilizing these tumors because of limited selectivity of the cytotoxic agents available. The thymidine analogue 5-iodo-2'-deoxyuridine (IdUrd) radiolabeled with 123I and 125I was injected directly into an intracerebral rat 9L gliosarcoma and found to be a sensitive and specific agent for the detection of this neoplasm in rats. External gamma camera imaging (123I) visualized tumors as small as 0.5 mm in diameter. Autoradiography (125I) indicated that IdUrd was incorporated into the DNA of neoplastic glia only. Since 123I emits gamma-photons suitable for scintigraphy, [123I]IdUrd holds promise for the diagnosis of brain tumors in humans as well. Furthermore, since 123I and 125I are Auger electron emitters that have demonstrated antineoplastic effects, direct administration of [123I]IdUrd or [125I]IdUrd into tumors may also have potential for the treatment of central nervous system malignancies.
Other Available Sources
Terms of Use
Metadata Only
Collection